1. Egyptian Perspective On Prediabetes & Diabetes
Ibrahim El Ebrashy
Prof. Of Internal Medicine & Diabetes
Faculty Of Medicine-Cairo University
Dean
National Institute Of Diabetes & Endocrinology (NIDE )
Cairo – MOH
Egypt

2. Top 10 prevalence of diabetes (20-79 age groups) in 2007 (With 2025 prevalence)
Country
Nauru
UAE
Saudi Arabia
2007
Bahrain
2025
Kuwait
Oman
Tonga
Mauritius
Egypt
Mexico
Prevalence (%) 5 10 15 20 25 30 35 40
International Diabetes Federation. Diabetes Atlas. Brussels, Belgium: IDF; 2007

3. CHRONIC DISEASES a vital investment
Preventing
CHRONIC DISEASES
a vital investment
World Health
Organization 2007

4. The burden and costs of chronic diseases in low-income and middle-income countries
The Lancet , 5 December 2007

5. They estimated the burden and loss of economic output associated with chronic diseases in 23 selected countries
These countries were selected as leading countries collectively accounting for around 80% of the total mortality burden attributable to chronic diseases in developing countries.

6. They aggregate estimates from coronary heart disease, stroke, and diabetes, since these disorders represent the greatest burden of the entire group of chronic diseases.
All estimates are projected between 2005 and 2015.

9. Global Burden Of Diabetes Prevalence and Projections 2010 and 2030 IDF, 2009.

10. Number of people with diabetes (20-79 years) 2010 and 2030
TOP 10

11. T2DM trends in Egypt- Prevalence15 25 - 34 35 - 44
Age Categories 45 - 54
10.4 55 - 65 10
8.6
Prevalence (%)
8.8 %
7.0
20.3 %
42.6 % 5
28.3 %
Male
Female
Total
Egyptian Ministry of Health (MOH ) Preventive Sector, Central Epidemiology and Disease Surveillance (ESU) 2006

12. T2DM trends in Egypt (%) OAD use Insulin use Prevalence Undiagnosed 25
Age Categories 25 25 - 34 35 - 44 20 45 - 54 55 - 65 15
(%)
Total 10 5
OAD
use
Insulin
use
Prevalence
Undiagnosed
Egyptian Ministry of Health (MOH) Preventive Sector, Central Epidemiology and Disease Surveillance (ESU) 2006

13. T2DM trends in Egypt- Complications & Risk factors ( NIDE Data 2008 )
BMI < 25
BMI 25-30
BMI > 30
High
Cholesterol
Low HDL
Hypertension
Retinopathy
Nephropathy
Neuropathy 10 20 30 40 50 60 70 80 90
Prevalence (%)

14. T2DM trends in Egypt-Metabolic Syndrome NIDE Data 2008
90 % of T2DM patients in Egypt have Metabolic Syndrome

15. T1DM trends in Egypt NIDE Data 2009 ( 852 Patients )

16. Hereditary factors

17. Infant feeding

18. Age of onset of diabetes

19. BMI in diabetic children

20. HbA1c among diabetic children

21. Beta cell function among diabetic children

22. Continues Home Blood Glucose Monitoring

23. MOH – Curative Care Sector Project: Early Detection of Diabetes Mellitus
Salah El-Ghazaly Harb*, Ibrahim El-Ebrashy***,
Mohamed Fahmy** and Madiha Said Abdel-Razik*
Faculty of Medicine Cairo* and Ain Shams** Universities and the National Institute For Diabetes & Endocrinology***

24. The EDDP established "early detection of DM clinics (EDDMC) in 14 hospitals, in three phases.
These hospitals are located in 12 governorates and distributed in the three Egypt Regions (Urban governorates, Lower Egypt and Upper Egypt).
Throughout the period , more than at-risk ≥ 25 years of age individuals (hypertension, obesity, and positive family history of diabetes), but with negative history of DM had been examined.

27. Egypt
Country profile
Percent with diabetes (20-79 years), 2010 (national)
10.4
Percent with diabetes (20-79 years), 2010 (comparative)
11.4
Percent with diabetes (20-79 years), 2030 (comparative)
13.7
Number of people with diabetes, 2010
4,787,100

28. Percent with impaired glucose tolerance (20-79 years), 2010 (national)
4.8
Percent with impaired glucose tolerance (20-79 years), 2010 (comparative)
5.1
New cases of type 1 diabetes in children (under 14 years) 2010 (new cases per 100,000 population per year)
8.0
Deaths attributable to diabetes (20-79 years), 2010
58,116
Mean health expenditure per person with diabetes (USD), R=2, 2010
116

30. T2DM trends in Egypt- Current treatment practice
Guidelines followed
Majority follow ADA , EASD & IDF guidelines
local clinical practice recommendation since 2009 MOH.
Management Practices
All oral anti-diabetic drugs available
Metformin remains the mainstay of treatment together with SUs.
TZDs are prescribed after failure of Metformin and SUs.
Newer agents like DPP-IV are launched in the market.
All types of insulin and insulin analogues are available.
National DPP is just launched

31. Thank You